Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medium- to Long-Term Metabolic Effects of IL-17/23 Biologics in Psoriasis
ChiCTR2600120423Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of guselkumab in plaque psoriasis (2 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Metabolic indicators (primary) at 104 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2600120423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120423.